Leading Scientists from Pharma, Biotech and Academia Will Speak and Force Debate at PharmaDiscovey 2005.

NORWALK, Conn. -- PharmaDiscovery, produced by Elsevier's Drug Discovery Today and Reed Exhibitions, announces a leading scientific line-up of speakers from the drug discovery community at PharmaDiscovery on May 10-12, 2005 at the Washington, D.C. Convention Center.

PharmaDiscovery is an event that will convey the scientific expertise and global reach of Elsevier in a new, knowledge-based forum combining pure scientific insight with drug discovery technology.

"We are privileged to have so many elite members of the drug discovery community who have accepted our invitation to speak and who support a purely scientific event that will force debate on the critical issues preventing the closure of the drug discovery productivity gap," said Kevin Richards, Industry Vice President, Reed Exhibitions.

The conference program has been developed by chairs and co-chairs to actively encourage scientific debate and audience participation. Presentations, lead by scientists, will focus on clear objectives and tackle key issues within each discipline. The conference will have daily sum-up sessions that will integrate and disseminate scientific knowledge, and relay the key points and conclusions from each session back to the entire audience, facilitating the exchange of information between chemists and biologists, and helping to break down drug discovery silos.

The conference sessions focus on the convergence of scientific insight and drug discovery technologies and include: Pharmacological Models for Human Diseases, Target Assessment, IT Infrastructure as a Source of Value Creation for the Drug Discovery Process, In Silico Drug Discovery, Chemistry Driven Drug Discovery: Proof of Concept Ligands, Evaluating Success in Drug Discovery: Where We Are and Where We Go Next, In Vivo Models in Drug Development, Pre-Clinical Safety & Drug Development, Data Integration, Efficacy Biomarkers in Early Clinical Development: Stop/Go Decision Makers or Risk Management Tools?, Chemistry Driven Drug Discovery: Breakthrough Medicines , and focused sessions on Biomarker Technologies, GPCRs, Kinases, Ion Channels and Proteases.

The speaker line-up includes:

Dr Dimitris Agrafiotis, Senior Research Fellow and Team Leader, Molecular Design and Informatics, Johnson & Johnson; Dr Martyn Banks, Director of Drug Discovery, Bristol Myers Squibb; Dr John Brown, Global Head of Translational Medicine and Technology, GlaxoSmithKline; Dr Bruce Car, Executive Director, Discovery Toxicology, Bristol Myers Squibb; Dr Wendy Cornell, Director of Molecular Systems, Merck; Dr Carlos Garcia Escheverria, Novartis Institutes for BioMedical Research, Dr Frank Gonzalez, Chief of Laboratory of Metabolism, Centre for Cancer Research, National Cancer Institute, National Institutes of Health; Dr Val Goodfellow, Associate Director, Neurocrine Biosciences; Dr Peter Haddock, Ion Channel Pharmacology Group Leader, Pfizer Ann Arbor Laboratories; Dr Kenneth Jacobson, Molecular Recognition Section Chief, Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health; Dr Ken Korzekwa, Director, Pre-Clinical Drug Metabolism, Merck; Dr Peter Lord, Director of Mechanistic Toxicology, Johnson & Johnson; Dr Mike Luther, Vice President Discovery Research, GlaxosmithKline; Professor Graeme Milligan, Institute of Biomedical and Life Sciences, University of Glasgow; Dr Mark Murcko, Chief Technology Officer, Vertex Pharmaceuticals; Professor Steve Naylor, Computational Systems Biology Initiative, Massachusetts Institute of Technology; Professor Patrick Nef, Head Molecular Neurobiology, F. Hoffmann-La Roche, Ltd; Dr Eric Neumann, Global Head of Knowledge Management, Aventis Drug Innovation and Approval; Professor Bernhard Palsson, Dept of Bioengineering, University of California, San Diego; Dr Anthony G Quinn, Vice President Discovery Medicine, Roche Palo Alto; Professor Andy Randall, Director of Neurophysiology Neurology and GI CEDD, GlaxoSmithKline; Dr. Jack Reynolds, Global Head of Safety Sciences, Pfizer Research and Development; Dr Edward A. Sausville, Greenebaum Cancer Center, University of Maryland at Baltimore; Professor Thue Schwartz, Chief Scientific Officer, 7TM Pharma A/S; Dr Ronald Shymko, Head of Scientific Computing, Novo Nordisk; Dr James Stevens, Research Fellow, Toxicology and Drug Disposition, Lilly Research Laboratories; Dr James Summers, Divisional Vice President, Advanced Technology, Abbott Laboratories; Dr Hans Winkler, Senior Director of Functional Genomics, Johnson & Johnson; Dr Richard Woychik, Director, The Jackson Laboratory

Exhibit Hall

PharmaDiscovery will attract members of the academic and pharmaceutical scientific R&D communities, regulatory authorities and developers and suppliers of critical technologies. An exhibit hall will feature exhibitors in categories such as automation integration, chemistry-related products, contract research, sample preparation, microarray products, custom databases, lab equipment, proteomics, screening and assay tools. Exhibitors include: Apple Computer, Inc., CambridgeSoft Corporation, CEM Corporation, ChromaVision Medical Systems, Inc., Drug Discovery Today, EMD Biosciences, Inc., Fujitsu America, In Vitro Technologies, Key Organics Ltd, MDL Information Systems Inc., Metabolon, Molecular Devices Corporation, Nature Publishing Group, NeuroScience Associates, Pharmacore, Inc. RBI US Life Science Group, sciencejobs.com, SelectScience and more.

Organizers

Elsevier is the respected global leader in scientific, technical and medical products including the highly regarded journals Drug Discovery Today, Cell, Tetrahedron, the Lancet, and the renowned scientific information platform, ScienceDirect. Other endorsing Reed Elsevier groups focused on drug discovery solutions include the Reed Business Information Science Group (Drug Discovery & Development Magazine, Bioscience Technology, Scientific Computing & Instrumentation Magazine, Genomics & Proteomics, Laboratory Equipment and R&D Magazine), MDL, and ScienceJobs.com/New Scientist.

The event will be produced and managed by Reed Exhibitions, the world's leading organizer of business-to-business events. Reed events are held in 35 countries and are organized by 30 international offices serving 49 industries.

For more information about PharmaDiscovery, visit: www.pharmadiscovery2005.com or contact Kevin C. Richards at [phone] or [e-mail].